The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and
Pseudomonas are increasingly reported worldwide and are usually associated with high …

Background In vitro data support the use of combination of aztreonam (ATM) with
ceftazidime-avibactam (CAZ-AVI), but clinical studies are lacking. The aim of our study was …

Carbapenem-resistant Enterobacterales (CRE) are a growing threat to human health
worldwide. CRE often carry multiple resistance genes that limit treatment options and …

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent
one of the most common hospital-acquired infections, carrying a significant morbidity and …

The spread of metallo-β-lactamase (MBL)-producing Enterobacterales worldwide without
the simultaneous increase in active antibiotics makes these organisms an urgent public …

The spread of multidrug-resistant (MDR), metallo-β-lactamase (MBL)-producing Klebsiella
pneumoniae represents a major therapeutic challenge. The newly introduced β-lactam-β …

Background Aztreonam is a monobactam stable to hydrolysis by metallo-β-lactamases
(MBLs) and avibactam is a non-β-lactam β-lactamase inhibitor that effectively inhibits serine …

Background As the frequency of metallo-β-lactamase (MBL)-producing Enterobacterales is
increasing worldwide, effective antimicrobials to treat the infections caused by these …

Gram-negative bacterial resistance to antimicrobials has had an exponential increase at a
global level during the last decades and represent an everyday challenge, especially for the …